SCHEMBL483753

SCHEMBL483753

CN(C(=O)O)c1ccc(-c2cnc3ccccc3c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
MAP4K4 O95819 1/20 0.53
CSNK1G2 P78368 1/20 0.53
CLK4 Q9HAZ1 1/20 0.53
MKNK2 Q9HBH9 1/20 0.53
MAP4K5 Q9Y4K4 1/20 0.53
PDGFRB P09619 2/20 0.53
PDGFRA P16234 2/20 0.53
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA9 Q16790 1/20 0.52
MGAM O43451 1/20 0.49
PIK3CD O00329 2/20 0.48
PIK3CA P42336 2/20 0.48
CYP2A6 P11509 1/20 0.47
NR2F2 P24468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL483842 0.82 PAX8 (0.60) KDM4ENPC1RAB9ASMN1; SMN2MAP4K4
SCHEMBL29378182 0.82 CYP1A2 (0.64) KDM4ESMN1; SMN2MAP4K4CSNK1G2CLK4
SCHEMBL24621829 0.79 PDGFRB (0.72) KDM4ENPC1RAB9AMAP4K4CSNK1G2
SCHEMBL26829682 0.79 PDGFRB (0.72) KDM4ENPC1RAB9AMAP4K4CSNK1G2
SCHEMBL29375510 0.79 PDGFRB (0.72) KDM4ENPC1RAB9AMAP4K4CSNK1G2
SCHEMBL8109340 0.79 MGAM (0.68) MAP4K4CSNK1G2CLK4MKNK2MAP4K5
SCHEMBL24229577 0.78 PDGFRB (0.66) NPC1RAB9AMAP4K4CSNK1G2CLK4
SCHEMBL24229569 0.78 PDGFRB (0.66) NPC1RAB9AMAP4K4CSNK1G2CLK4
SCHEMBL1730118 0.78 ALDH1A1 (0.48) KDM4ENPC1RAB9ASMN1; SMN2FASN
SCHEMBL708999 0.78 PDGFRB (0.75) KDM4ENPC1RAB9ASMN1; SMN2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411057-B1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS LILLY CO ELI (US) 2020-05-06 EP disclosed
EP-2550255-B1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS LILLY CO ELI (US) 2016-04-27 EP disclosed
US-20130302248-A1 Imaging Agents for Detecting Neurological Disorders LILLY CO ELI (US) 2013-11-14 US disclosed
US-8491869-B2 Imaging agents for detecting neurological disorders ELI LILLY AND COMPANY (US) 2013-07-23 US disclosed
EP-2411057-A2 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS Siemens Medical Solutions USA, Inc. (US) 2012-02-01 EP disclosed
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-07-28 US disclosed
WO-2010111303-A2 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-09-30 WO disclosed
US-20100239496-A1 Imaging agents for detecting neurological disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130302248-A1 Imaging Agents for Detecting Neurological Disorders MAPT, APP, PSEN1 KDM4E 4835/4885NPC1 68/4885RAB9A 1055/4885
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders MAPT, APP, PSEN1 KDM4E 4835/4885NPC1 143/4885RAB9A 1434/4885
US-20100239496-A1 Imaging agents for detecting neurological disorders MAPT, APP, PSEN1 KDM4E 4835/4885NPC1 68/4885RAB9A 1055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.